Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience

Mazyar Shadman, David G. Maloney, Barry Storer, Brenda M. Sandmaier, Thomas R. Chauncey, Niels Smedegaard Andersen, Dietger Niederwieser, Judith Shizuru, Benedetto Bruno, Michael A. Pulsipher, Richard Maziarz, Edward D. Agura, Parameswaran Hari, Amelia A. Langston, Michael B. Maris, Peter A. McSweeney, Rainer Storb, Mohamed L. Sorror

Research output: Contribution to journalArticle

Abstract

Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would reduce the relapse risk compared with historical controls (n = 157). Patients (n = 55) received fludarabine and low-dose total body irradiation combined with rituximab on days −3, + 10, + 24, + 36. Relapse rate at 3 years was significantly lower among rituximab-treated patients versus controls (17% versus 31%; P = 0.04). Overall survival (OS), progression-free survival (PFS) and nonrelapse mortality (NRM) were statistically similar: (53% versus 50%; P = 0.8), (44% versus 42%; P = 0.63), and (38% versus 28%; P = 0.2), respectively. In multivariate analysis, rituximab treatment was associated with lower relapse rates both in the overall cohort [hazard ratio (HR): 0.34, P = 0.006] and in patients with high-risk cytogenetics (HR: 0.21, P = 0.0003). Patients with no comorbidities who received rituximab conditioning had an OS rate of 100% and 75% at 1 and 3 years, respectively, with no NRM. Peri-transplant rituximab reduced relapse rates regardless of high-risk cytogenetics. HCT is associated with minimal NRM in patients without comorbidities and is a viable option for patients with high-risk CLL. Clinical trial information: NCT00867529.

Original languageEnglish (US)
JournalBone marrow transplantation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Transplants
Recurrence
Cell Transplantation
Cytogenetics
Mortality
Comorbidity
Whole-Body Irradiation
Disease-Free Survival
Rituximab
Multivariate Analysis
Survival Rate
Clinical Trials
Survival

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Shadman, M., Maloney, D. G., Storer, B., Sandmaier, B. M., Chauncey, T. R., Smedegaard Andersen, N., ... Sorror, M. L. (Accepted/In press). Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. Bone marrow transplantation. https://doi.org/10.1038/s41409-019-0660-8

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. / Shadman, Mazyar; Maloney, David G.; Storer, Barry; Sandmaier, Brenda M.; Chauncey, Thomas R.; Smedegaard Andersen, Niels; Niederwieser, Dietger; Shizuru, Judith; Bruno, Benedetto; Pulsipher, Michael A.; Maziarz, Richard; Agura, Edward D.; Hari, Parameswaran; Langston, Amelia A.; Maris, Michael B.; McSweeney, Peter A.; Storb, Rainer; Sorror, Mohamed L.

In: Bone marrow transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Shadman, M, Maloney, DG, Storer, B, Sandmaier, BM, Chauncey, TR, Smedegaard Andersen, N, Niederwieser, D, Shizuru, J, Bruno, B, Pulsipher, MA, Maziarz, R, Agura, ED, Hari, P, Langston, AA, Maris, MB, McSweeney, PA, Storb, R & Sorror, ML 2019, 'Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience', Bone marrow transplantation. https://doi.org/10.1038/s41409-019-0660-8
Shadman, Mazyar ; Maloney, David G. ; Storer, Barry ; Sandmaier, Brenda M. ; Chauncey, Thomas R. ; Smedegaard Andersen, Niels ; Niederwieser, Dietger ; Shizuru, Judith ; Bruno, Benedetto ; Pulsipher, Michael A. ; Maziarz, Richard ; Agura, Edward D. ; Hari, Parameswaran ; Langston, Amelia A. ; Maris, Michael B. ; McSweeney, Peter A. ; Storb, Rainer ; Sorror, Mohamed L. / Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. In: Bone marrow transplantation. 2019.
@article{62237b95ab204f508ea53c6379fca3f4,
title = "Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience",
abstract = "Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would reduce the relapse risk compared with historical controls (n = 157). Patients (n = 55) received fludarabine and low-dose total body irradiation combined with rituximab on days −3, + 10, + 24, + 36. Relapse rate at 3 years was significantly lower among rituximab-treated patients versus controls (17{\%} versus 31{\%}; P = 0.04). Overall survival (OS), progression-free survival (PFS) and nonrelapse mortality (NRM) were statistically similar: (53{\%} versus 50{\%}; P = 0.8), (44{\%} versus 42{\%}; P = 0.63), and (38{\%} versus 28{\%}; P = 0.2), respectively. In multivariate analysis, rituximab treatment was associated with lower relapse rates both in the overall cohort [hazard ratio (HR): 0.34, P = 0.006] and in patients with high-risk cytogenetics (HR: 0.21, P = 0.0003). Patients with no comorbidities who received rituximab conditioning had an OS rate of 100{\%} and 75{\%} at 1 and 3 years, respectively, with no NRM. Peri-transplant rituximab reduced relapse rates regardless of high-risk cytogenetics. HCT is associated with minimal NRM in patients without comorbidities and is a viable option for patients with high-risk CLL. Clinical trial information: NCT00867529.",
author = "Mazyar Shadman and Maloney, {David G.} and Barry Storer and Sandmaier, {Brenda M.} and Chauncey, {Thomas R.} and {Smedegaard Andersen}, Niels and Dietger Niederwieser and Judith Shizuru and Benedetto Bruno and Pulsipher, {Michael A.} and Richard Maziarz and Agura, {Edward D.} and Parameswaran Hari and Langston, {Amelia A.} and Maris, {Michael B.} and McSweeney, {Peter A.} and Rainer Storb and Sorror, {Mohamed L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41409-019-0660-8",
language = "English (US)",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience

AU - Shadman, Mazyar

AU - Maloney, David G.

AU - Storer, Barry

AU - Sandmaier, Brenda M.

AU - Chauncey, Thomas R.

AU - Smedegaard Andersen, Niels

AU - Niederwieser, Dietger

AU - Shizuru, Judith

AU - Bruno, Benedetto

AU - Pulsipher, Michael A.

AU - Maziarz, Richard

AU - Agura, Edward D.

AU - Hari, Parameswaran

AU - Langston, Amelia A.

AU - Maris, Michael B.

AU - McSweeney, Peter A.

AU - Storb, Rainer

AU - Sorror, Mohamed L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would reduce the relapse risk compared with historical controls (n = 157). Patients (n = 55) received fludarabine and low-dose total body irradiation combined with rituximab on days −3, + 10, + 24, + 36. Relapse rate at 3 years was significantly lower among rituximab-treated patients versus controls (17% versus 31%; P = 0.04). Overall survival (OS), progression-free survival (PFS) and nonrelapse mortality (NRM) were statistically similar: (53% versus 50%; P = 0.8), (44% versus 42%; P = 0.63), and (38% versus 28%; P = 0.2), respectively. In multivariate analysis, rituximab treatment was associated with lower relapse rates both in the overall cohort [hazard ratio (HR): 0.34, P = 0.006] and in patients with high-risk cytogenetics (HR: 0.21, P = 0.0003). Patients with no comorbidities who received rituximab conditioning had an OS rate of 100% and 75% at 1 and 3 years, respectively, with no NRM. Peri-transplant rituximab reduced relapse rates regardless of high-risk cytogenetics. HCT is associated with minimal NRM in patients without comorbidities and is a viable option for patients with high-risk CLL. Clinical trial information: NCT00867529.

AB - Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would reduce the relapse risk compared with historical controls (n = 157). Patients (n = 55) received fludarabine and low-dose total body irradiation combined with rituximab on days −3, + 10, + 24, + 36. Relapse rate at 3 years was significantly lower among rituximab-treated patients versus controls (17% versus 31%; P = 0.04). Overall survival (OS), progression-free survival (PFS) and nonrelapse mortality (NRM) were statistically similar: (53% versus 50%; P = 0.8), (44% versus 42%; P = 0.63), and (38% versus 28%; P = 0.2), respectively. In multivariate analysis, rituximab treatment was associated with lower relapse rates both in the overall cohort [hazard ratio (HR): 0.34, P = 0.006] and in patients with high-risk cytogenetics (HR: 0.21, P = 0.0003). Patients with no comorbidities who received rituximab conditioning had an OS rate of 100% and 75% at 1 and 3 years, respectively, with no NRM. Peri-transplant rituximab reduced relapse rates regardless of high-risk cytogenetics. HCT is associated with minimal NRM in patients without comorbidities and is a viable option for patients with high-risk CLL. Clinical trial information: NCT00867529.

UR - http://www.scopus.com/inward/record.url?scp=85072196038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072196038&partnerID=8YFLogxK

U2 - 10.1038/s41409-019-0660-8

DO - 10.1038/s41409-019-0660-8

M3 - Article

C2 - 31481800

AN - SCOPUS:85072196038

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -